Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

DHA-paclitaxel

Drug Profile

DHA-paclitaxel

Alternative Names: Paclitaxel-DHA conjugate; Paclitaxel-docosahexaenoic acid conjugate; Taxoprexin

Latest Information Update: 04 Jan 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Luitpold Pharmaceuticals
  • Class Antineoplastics; Paclitaxels; Taxanes
  • Mechanism of Action Mitosis inhibitors; Tubulin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Biliary cancer; Breast cancer; Colorectal cancer; Gastric cancer; Liver cancer; Malignant melanoma; Non-small cell lung cancer; Pancreatic cancer; Prostate cancer; Renal cancer; Solid tumours

Most Recent Events

  • 02 Jan 2019 Luitpold Pharmaceuticals is now called American Regent
  • 24 Jun 2018 Biomarkers information updated
  • 08 May 2017 Luitpold Pharmaceuticals terminated a phase II trial in Liver cancer and biliary cancer (Late-stage disease, Second-line therapy or greater, Metastatic disease, Inoperable/Unresectable) in USA as the sponsor suspended the development of the drug (IV-infusion) (NCT00422877)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top